Журнал «Медицина неотложных состояний» Том 20, №7, 2024

Перипартальна кардіоміопатія (ПКМП) — це кардіоміопатія із порушенням систолічної функції лівого шлуночка, яка розвивається у вагітних або у перші місяці після пологів. Клінічні прояви можуть варіювати від незначних або помірних до вираженої симптоматики серцевої недостатності зі значним обмеженням функціональних можливостей та високим рівнем летальності. ПКМП має досить гетерогенну та неповністю вивчену патофізіологію, що включає гормональні, судинні, метаболічні, імунологічні шляхи розвитку, реалізація яких стає можливою на фоні генетичної схильності пацієнтки до розвитку захворювання. Лікування базується на терапії серцевої недостатності з огляду на ризики, пов'язані з вагітністю та вигодовуванням. Як специфічна терапія розглядається призначення бромокриптину, втім, рівень доказовості такого лікування є недостатнім. У статті висвітлені основні відомості про патофізіологію, діагностику, прогноз, профілактику та лікування ПКМП на сучасному етапі. Пошук літератури при написанні цього огляду проводився по базах даних MedLine, Scopus та Web of Science.

Peripartum cardiomyopathy (PCMP) is cardiomyo-pathy with left ventricular systolic dysfunction that develops in late pregnancy or in the first months of postpartum period. Clinical manifestations can vary from mild or moderate to severe symptoms of heart failure with significant functional limitation and high mortality. PCMP has a rather heterogeneous and incompletely studied pathophysiology, which includes hormonal, vascular, metabolic, and immunological pathways, whose implementation becomes possible on the background of genetic predisposition. Treatment is based on heart failure therapy, taking into account the risks associated with pregnancy and lactation. Bromocriptine is being considered as a specific therapy; however, the level of evidence for such treatment is insufficient. The article covers basic information about the pathophysiology, diagnosis, prognosis, prevention and treatment of PCMP at the current stage. For writing this review, the literature search was conducted using the MEDLINE, Scopus, and Web of Science databases.

перипартальна кардіоміопатія; діагностика; лікування; огляд

peripartum cardiomyopathy; diagnosis; treatment; review

1. Hull EHF. Toxic postpartum heart disease. New Orleans Med Surg J.1937;89:550-557.
2. Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019 Jul;21(7):827-843. doi: 10.1002/ejhf.1493. Epub 2019 Jun 27. PMID: 31243866.
3. Jackson AM, Macartney M, Brooksbank K, et al. A 20-year population study of peripartum cardiomyopathy. Eur Heart J. 2023 Dec 21;44(48):5128-5141. doi: 10.1093/eurheartj/ehad626. PMID: 37804234; PMCID: PMC10733720.
4. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, Nakatani S, Murohara T, Tomoike H, Ikeda T. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J. 2011;75(8):1975-81. doi: 10.1253/circj.cj-10-1214. Epub 2011 May 27. PMID: 21617320.
5. Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn Dis. 2007 Spring;17(2):228-33. PMID: 17682350.
6. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005 Dec;80(12):1602-6. doi: 10.4065/80.12.1602. PMID: 16342653.
7. Hasan JA, Qureshi A, Ramejo BB, Kamran A. Peripartum cardiomyopathy characteristics and outcome in a tertiary care hospital. J Pak Med Assoc. 2010 May;60(5):377-80. PMID: 20527612.
8. Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL. African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol. 2010 Feb 16;55(7):654-9. doi: 10.1016/j.jacc.2009.09.043. PMID: 20170791; PMCID: PMC3814012.
9. Brar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, Shen AY. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007 Jul 15;100(2):302-4. doi: 10.1016/j.amjcard.2007.02.092. Epub 2007 Jun 6. PMID: 17631087.
10. Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the Uni–ted States: a nationwide population-based study. J Am Heart Assoc. 2014 Jun 4;3(3):e001056. doi: 10.1161/JAHA.114.001056. PMID: 24901108; PMCID: PMC4309108. 
11. Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol. 2013 Oct 29;62(18):1715-1723. doi: 10.1016/j.jacc.2013.08.717. Epub 2013 Sep 4. PMID: 24013055; PMCID: PMC3931606.
12. Arany Z. Peripartum Cardiomyopathy. N Engl J Med. 2024 Jan 11;390(2):154-164. doi: 10.1056/NEJMra2306667. PMID: 38197818.
13. Davis MB, Jarvie J, Gambahaya E, Lindenfeld J, Kao D. Risk Prediction for Peripartum Cardiomyopathy in Delivering Mothers: A Validated Risk Model: PPCM Risk Prediction Model. J Card Fail. 2021 Feb;27(2):159-167. doi: 10.1016/j.cardfail.2020.12.022. Epub 2020 Dec 31. PMID: 33388467.
14. Liu LX, Arany Z. Maternal cardiac metabolism in pregnancy. Cardiovasc Res. 2014 Mar 15;101(4):545-53. doi: 10.1093/cvr/cvu009. Epub 2014 Jan 20. PMID: 24448314; PMCID: PMC3941596.
15. Fett JD, Ansari AA, Sundstrom JB, Combs GF. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int J Cardiol. 2002 Dec;86(2-3):311-6. doi: 10.1016/s0167-5273(02)00359-5. PMID: 12419571.
16. Fett JD. Viral infection as a possible trigger for the deve-lopment of peripartum cardiomyopathy. Int J Gynaecol Obstet. 2007 May;97(2):149-50. doi: 10.1016/j.ijgo.2007.01.012. Epub 2007 Mar 21. PMID: 17368646.
17. Haghikia A, Kaya Z, Schwab J, et al. Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Res Cardiol. 2015 Nov;110(6):60. doi: 10.1007/s00395-015-0517-2. Epub 2015 Oct 30. PMID: 26519371.
18. Sliwa K, Förster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006 Feb;27(4):441-6. doi: 10.1093/eurheartj/ehi481. Epub 2005 Sep 5. PMID: 16143707.
19. Toescu V, Nuttall SL, Martin U, Kendall MJ, Dunne F. Oxidative stress and normal pregnancy. Clin Endocrinol (Oxf). 2002 Nov;57(5):609-13. doi: 10.1046/j.1365-2265.2002.01638.x. PMID: 12390334.
20. Ricke-Hoch M, Pfeffer TJ, Hilfiker-Kleiner D. Peripartum cardiomyopathy: basic mechanisms and hope for new therapies. Cardiovasc Res. 2020 Mar 1;116(3):520-531. doi: 10.1093/cvr/cvz252. PMID: 31605117.
21. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007 Feb 9;128(3):589-600. doi: 10.1016/j.cell.2006.12.036. PMID: 17289576.
22. Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013 May;123(5):2143-54. doi: 10.1172/JCI64365. Epub 2013 Apr 24. PMID: 23619365; PMCID: PMC3638905.
23. Costa MA. The endocrine function of human placenta: an overview. Reprod Biomed Online. 2016 Jan;32(1):14-43. doi: 10.1016/j.rbmo.2015.10.005. Epub 2015 Oct 27. PMID: 26615903.
24. Damp J, Givertz MM, Semigran M, et al.; IPAC Investigators. Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study. JACC Heart Fail. 2016 May;4(5):380-8. doi: 10.1016/j.jchf.2016.01.004. Epub 2016 Mar 9. PMID: 26970832; PMCID: PMC4851559.
25. Roh JD, Castro C, Yu A, et al. Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human. Sci Transl Med. 2024 Apr 17;16(743):eadi0077. doi: 10.1126/scitranslmed.adi0077. Epub 2024 Apr 17. PMID: 38630848.
26. Feridooni HA, MacDonald JK, Ghimire A, Pyle WG, Howlett SE. Acute exposure to progesterone attenuates cardiac contraction by modifying myofilament calcium sensitivity in the female mouse heart. Am J Physiol Heart Circ Physiol. 2017 Jan 1;312(1):H46-H59. doi: 10.1152/ajpheart.00073.2016. Epub 2016 Oct 28. PMID: 27793852; PMCID: PMC5283917.
27. Goli R, Li J, Brandimarto J, Levine LD, et al. Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation. 2021 May 11;143(19):1852-1862. doi: 10.1161/CIRCULATIONAHA.120.052395. Epub 2021 Apr 20. PMID: 33874732; PMCID: PMC8113098.
28. Arany Z. It Is Time to Offer Genetic Testing to Women with Peripartum Cardiomyopathy. Circulation. 2022 Jul 5;146(1):4-5. doi: 10.1161/CIRCULATIONAHA.122.059177. Epub 2022 Jul 5. PMID: 35858163; PMCID: PMC9310056.
29. Jackson AM, Macartney M, Brooksbank K, et al. A 20-year population study of peripartum cardiomyopathy. Eur Heart J. 2023 Dec 21;44(48):5128-5141. doi: 10.1093/eurheartj/ehad626. PMID: 37804234; PMCID: PMC10733720.
30. Hu CL, Li YB, Zou YG, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardio-
31. myopathy. Heart. 2007 Apr;93(4):488-90. doi: 10.1136/hrt.2006.087387. Epub 2006 Oct 25. PMID: 17065185; PMCID: PMC1861492.
32. Hoevelmann J, Engel ME, Muller E, Hohlfeld A, Böhm M, Sliwa K, Viljoen C. A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis. Eur J Heart Fail. 2022 Sep;24(9):1719-1736. doi: 10.1002/ejhf.2603. Epub 2022 Jul 26. PMID: 35778990.
33. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006 Sep;152(3):509-13. doi: 10.1016/j.ahj.2006.02.008. PMID: 16923422.
34. Haghikia A, Röntgen P, Vogel-Claussen J, et al. Prognostic implication of right ventricular involvement in peripartum cardio-myopathy: a cardiovascular magnetic resonance study. ESC Heart Fail. 2015 Dec;2(4):139-149. doi: 10.1002/ehf2.12059. Epub 2015 Sep 30. PMID: 27774259; PMCID: PMC5054874. 
35. Davis EM, Ewald G, Givertz MM, et al. Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy. Am J Perinatol. 2019 Apr;36(5):476-483. doi: 10.1055/s-0038-1669439. Epub 2018 Sep 5. PMID: 30184556.
36. Goland S, Modi K, Hatamizadeh P, Elkayam U. Differences in clinical profile of African-American women with peripartum cardiomyopathy in the United States. J Card Fail. 2013 Apr;19(4):214-8. doi: 10.1016/j.cardfail.2013.03.004. PMID: 23582086.
37. Lindley KJ, Conner SN, Cahill AG, Novak E, Mann DL. Impact of Preeclampsia on Clinical and Functional Outcomes in Women with Peripartum Cardiomyopathy. Circ Heart Fail. 2017 Jun;10(6):e003797. doi: 10.1161/CIRCHEARTFAILURE.116.003797. PMID: 28572214; PMCID: PMC5520674.
38. Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2008 Sep;10(9):861-8. doi: 10.1016/j.ejheart.2008.07.005. Epub 2008 Sep 2. PMID: 18768352. 
39. Xu H, Zhao L, Fu H, et al. Prognostic Value of Cardiac MRI Late Gadolinium Enhancement in Patients with Peripartum Cardiomyopathy: A Retrospective Study. Curr Probl Cardiol. 2023 Apr;48(4):101587. doi: 10.1016/j.cpcardiol.2023.101587. Epub 2023 Jan 9. PMID: 36634831.
40. McNamara DM, Starling RC, Cooper LT, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol. 2011 Sep 6;58(11):1112-8. doi: 10.1016/j.jacc.2011.05.033. Erratum in: J Am Coll Cardiol. 2011 Oct 18;58(17):1832. PMID: 21884947; PMCID: PMC6467576.
41. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018 Sep 7;39(34):3165-3241. doi: 10.1093/eurheartj/ehy340. PMID: 30165544. 
42. McNamara DM, Elkayam U, Alharethi R, et al. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015 Aug 25;66(8):905-14. doi: 10.1016/j.jacc.2015.06.1309. PMID: 26293760; PMCID: PMC5645077. 
43. Loyaga-Rendon RY, Pamboukian SV, Tallaj JA, Acharya D, Cantor R, Starling RC, Naftel D, Kirklin J. Outcomes of patients with peripartum cardiomyopathy who received mechanical circulatory support. Data from the Interagency Registry for Mechanically Assisted Circulatory Support. Circ Heart Fail. 2014 Mar 1;7(2):300-9. doi: 10.1161/CIRCHEARTFAILURE.113.000721. Epub 2014 Jan 17. PMID: 24443515.
44. Gevaert S, Van Belleghem Y, Bouchez S, et al. Acute and critically ill peripartum cardiomyopathy and 'bridge to' therapeutic options: a single center experience with intra-aortic balloon pump, extra corporeal membrane oxygenation and continuous-flow left ventricular assist devices. Crit Care. 2011;15(2):R93. doi: 10.1186/cc10098. Epub 2011 Mar 10. PMID: 21392383; PMCID: PMC3219357.
45. Rasmusson K, Brunisholz K, Budge D, et al. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant. 2012 Feb;31(2):180-6. doi: 10.1016/j.healun.2011.11.018. PMID: 22305380.
46. Stapel B, Kohlhaas M, Ricke-Hoch M, et al. Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy. Eur Heart J. 2017 Feb 1;38(5):349-361. doi: 10.1093/eurheartj/ehw086. PMID: 28201733; PMCID: PMC5381590.
47. Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012 Aug 23;159(2):82-7. doi: 10.1016/j.ijcard.2011.07.022. Epub 2011 Jul 23. PMID: 21784540.
48. Biteker M, Duran NE, Kaya H, et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol. 2011 Jul;100(7):571-7. 
49. doi: 10.1007/s00392-010-0279-7. Epub 2011 Jan 1. PMID: 21197536.
50. Benlolo S, Lefoll C, Katchatouryan V, Payen D, Mebazaa A. Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth Analg. 2004 Mar;98(3):822-4, table of contents. doi: 10.1213/01.ane.0000099717.40471.83. PMID: 14980944.
51. Brogly N, Guasch E, Puertas L, Alsina E, Lopez T, Gilsanz F. [Acute early postpartum cardiac failure associated with dilated cardiomyopathy: successful treatment with intra-aortic balloon counter-pulsation and levosimendan]. Ann Fr Anesth Reanim. 2010;29(11):807-810. doi: 10.1016/j.annfar.2010.08.008. 
52. Nieto Estrada VH, Molano Franco DL, Valencia Moreno AA, Rojas Gambasica JA, Jaller Bornacelli YE, Martinez Del Valle A. Reversion of Severe Mitral Insufficiency in Peripartum Cardiomyopathy Using Levosimendan. J Clin Med Res. 2015 Dec;7(12):998-1001. doi: 10.14740/jocmr2323w. Epub 2015 Oct 23. PMID: 26566415; PMCID: PMC4625822.
53. Benezet-Mazuecos J, de la Hera J. Peripartum cardiomyopathy: a new successful setting for levosimendan. Int J Cardiol. 2008 Jan 24;123(3):346-7. doi: 10.1016/j.ijcard.2006.11.171. Epub 2007 Feb 26. PMID: 17324479.
54. Kaur P, Kundra TS. Role of inhaled levosimendan in peripartum cardiomyopathy. Saudi J Anaesth. 2022 Oct-Dec;16(4):500-503. doi: 10.4103/sja.sja_297_22. Epub 2022 Sep 3. PMID: 36337420; PMCID: PMC9630672.
55. Kundra TS, Nagaraja PS, Bharathi KS, Kaur P, Manjunatha N. Inhaled levosimendan versus intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement. Ann Card Anaesth. 2018 Jul-Sep;21(3):328-332. doi: 10.4103/aca.ACA_19_18. PMID: 30052230; PMCID: PMC6078018.
56. Desai HN, Sangurima L, Malik MM, et al. Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: 
57. A Systematic Review. Cureus. 2023 Apr 19;15(4):e37844. doi: 10.7759/cureus.37844. PMID: 37214028; PMCID: PMC10198665.
58. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Jan 21;75(2):207-221. doi: 10.1016/j.jacc.2019.11.014. PMID: 31948651.
59. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010 Apr 6;121(13):1465-73. doi: 10.1161/CIRCULATIONAHA.109.901496. Epub 2010 Mar 22. Erratum in: Circulation. 2010 Jun 1;121(21):e425. Struhman, Ingrid [corrected to Struman, Ingrid]. PMID: 20308616.
60. Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 2013 Jul;108(4):366. doi: 10.1007/s00395-013-0366-9. Epub 2013 Jun 28. PMID: 23812247; PMCID: PMC3709080.
61. Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J 2017;38:2671-2679. https://doi.org/10.1093/eurheartj/ehx355.
62. Tremblay-Gravel M, Marquis-Gravel G, Avram R, et al. The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the BRO-HF retrospective cohort study. ESC Heart Fail. 2019 Feb;6(1):27-36. doi: 10.1002/ehf2.12376. Epub 2018 Nov 22. PMID: 30565890; PMCID: PMC6351886. 
63. Radakrishnan A, Dokko J, Pastena P, Kalogeropoulos AP. Thromboembolism in peripartum cardiomyopathy: a systematic review. J Thorac Dis. 2024 Jan 30;16(1):645-660. doi: 10.21037/jtd-23-945. Epub 2024 Jan 16. PMID: 38410599; PMCID: PMC10894371.
64. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail. 2016;18:1096-1105. doi: 10.1002/ejhf.586.
65. Bozkurt B, Colvin M, Cook J, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement from the American Heart Association. Circulation. 2016 Dec 6;134(23):e579-e646. doi: 10.1161/CIR.0000000000000455. Epub 2016 Nov 3. Erratum in: Circulation. 2016 Dec 6;134(23):e652. doi: 10.1161/CIR.0000000000000474. PMID: 27832612.
66. Goland S, Weinstein JM, Zalik A, Kuperstein R, Zilberman L, Shimoni S, Arad M, Ben Gal T, George J. Angiogenic Imbalance and Residual Myocardial Injury in Recovered Peripartum Cardiomyopathy Patients. Circ Heart Fail. 2016 Nov;9(11):e003349. doi: 10.1161/CIRCHEARTFAILURE.116.003349. PMID: 28029641.
67. Lampert MB, Weinert L, Hibbard J, Korcarz C, Lindheimer M, Lang RM. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):189-95. doi: 10.1016/s0002-9378(97)80034-8. PMID: 9024112.
68. Canobbio MM, Warnes CA, Aboulhosn J, et al. Management of Pregnancy in Patients with Complex Congenital Heart Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2017 Feb 21;135(8):e50-e87. doi: 10.1161/CIR.0000000000000458. Epub 2017 Jan 12. PMID: 28082385. 
69. Pachariyanon P, Bogabathina H, Jaisingh K, Modi M, Modi K. Long-Term Outcomes of Women with Peripartum Cardiomyopathy Having Subsequent Pregnancies. J Am Coll Cardiol. 2023 Jul 4;82(1):16-26. doi: 10.1016/j.jacc.2023.04.043. PMID: 37380299.